hiw are patients screened for glp-1 drugs in colorado Proposed bill looks to regulate compounded medications Medicare weight loss drugs: Who
Description
J Clin Endocrinol Metab 90(4):19291935
In the ATTAIN-2 trial (participants with obesity and type 2 diabetes), GI adverse event rates were somewhat higher than in ATTAIN-1: nausea 20.1-36.4% versus 8.4% with placebo, vomiting 12.8-23.1% versus 3.8%, diarrhea 21.3-27.4% versus 15.0%, and constipation 17.7-22.4% versus 7.8%
More recently, researchers have been testing GLP-1 receptor agonists in people with obesity
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes
By route of administration, the oral segment is expected to be the fastest-growing in the studied years
